Biogen
Neurology & CNS Therapeutics · Prescription Drugs

Biogen revenue, results and funding

Biogen filed revenue of $9.9B for 2025.

Data updated Nov 21, 2026 · Back to the company report
$9.9BRevenue, 2025
$1.3BNet income, 2025
BIIBNasdaq

Results by year

YearRevenueNet incomeTotal assetsLANG_CR_S_M_TAX_PAIDLANG_CR_S_M_TAX_EXPENSELANG_CR_S_M_BUYBACKSLANG_CR_S_M_CAPEXLANG_CR_S_M_SBCLANG_CR_S_M_RNDLANG_CR_S_M_OPERATING_INCOMELANG_CR_S_M_CASHLANG_CR_S_M_DEBTLANG_CR_S_M_ACQUISITIONS
2025$9.9B$1.3B$29.4B$864M$263.6M–$153.8M$290.8M$1.8B––$6.3B–
2024$9.7B$1.6B$28B$355.1M$273.8M$0$153.7M$291.2M$2B––$6.3B$1.1B
2023$9.8B$1.2B$26.8B$740.7M$135.3M$0$277M$264.2M$2.4B––$6.9B$6.9B
2022$10.2B$3B$24.6B$932.9M$632.8M$750M$240.3M$254.1M$2.2B––$6.3B–
2021$11B$1.6B$23.9B$247.9M$52.5M$1.8B$258.1M$238.6M$2.5B$2.8B–$6.3B–
2020$13.4B$4B$24.6B$906.7M$992.3M$6.7B$424.8M$198.3M$4B$4.6B–$7.4B–
2019$14.4B$5.9B$27.2B$1.1B$1.2B$5.9B$514.5M$182.3M$2.3B$7B$2.9B$4.5B$744.4M
2018$13.5B$4.4B$25.3B$1B$1.4B$4.4B$770.6M$157.5M$2.6B$5.9B$1.2B$5.9B$0
2017$12.3B$2.5B$23.7B$1.1B$2.5B$1.4B$867.4M$128M$2.3B$5.3B$1.6B$5.9B$0
2016$11.4B$3.7B$22.9B$1.6B$1.2B$1B$616.1M$154.8M$2B$5.2B$2.3B$6.5B$0
2015$10.8B$3.5B$19.5B$1.7B$1.2B$5B$643M$161.4M$2B$4.9B$1.3B$6.5B$198.8M
2014$9.7B$2.9B$14.3B$1.2B$989.9M$886.8M$287.8M$155.3M$1.9B$4B$1.2B$580.3M$0
2013$6.9B$1.9B$11.9B$643.2M$601M$400.3M$246.3M$136.3M$1.4B$2.5B$602.6M$592.4M$0
2012$5.5B$1.4B$10.1B$526.6M$470.6M$984.7M$254.5M$118.6M$1.3B$1.9B$570.7M$687.4M$72.4M
2011$5B$1.2B$9B$332.7M$444.5M$498M$208M$113M$1.2B$1.7B$514.5M$1B$5M
Sources: SEC

How to cite

Biogen, Financials. Alion, Nov 21, 2026. https://alion.io/company/biogen-2/financials

.json · .md · CC BY-SA 4.0